News
-
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Protagonist Therapeutics to host conference call and webcast on November 21st at 4:30 pm ET to announce oral peptide IL-17 antagonist development. Details: dial-in and webcast link provided -
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Protagonist announces positive Phase 3 ICONIC study results of icotrokinra, a first-in-class oral peptide for plaque psoriasis, achieving key endpoints and milestone payments under Johnson & Johnson collaboration -
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports financial results and upcoming milestones for Phase 3 clinical trials in psoriasis and ulcerative colitis, Phase 3 trials in polycythemia vera, and oral peptide antagonist development candidate nomination -
